Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists

Autor: Rolf Inderbitzi, Alexandros Papachristofilou, Francesca Caparrotti, Peter Kestenholz, Dirk Wagnetz, Paul Martin Putora, Hans Gelpke, André Dutly, Daniel R. Zwahlen, Markus Furrer, Mahmut Ozsahin, Thorsten Krueger, Peter Kraxner, Matthias Guckenberger, Isabelle Opitz, Stefano Cafarotti, Markus Glatzer, Jürg Heuberger, Pawel Leskow, Kathrin Zaugg, Olgun Elicin, Christoph Oehler, Francesco Martucci, Gregor J. Kocher, Franco Gambazzi, Wolfram Karenovics

Publikováno v: Transl Lung Cancer Res
Glatzer, Markus; Leskow, Pawel; Caparrotti, Francesca; Elicin, Olgun; Furrer, Markus; Gambazzi, Franco; Dutly, André; Gelpke, Hans; Guckenberger, Matthias; Heuberger, Jürg; Inderbitzi, Rolf; Cafarotti, Stefano; Karenovics, Wolfram; Kestenholz, Peter; Kocher, Gregor; Kraxner, Peter; Krueger, Thorsten; Martucci, Francesco; Oehler, Christoph; Ozsahin, Mahmut; ... (2021). Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists. Translational lung cancer research, 10(4), pp. 1960-1968. AME Publishing 10.21037/tlcr-20-1210
Translational lung cancer research, Vol. 10, No 4 (2021) pp. 1960-1968

Background Stage III N2 non-small cell lung cancer (NSCLC) is a very heterogeneous disease associated with a poor prognosis. A number of therapeutic options are available for patients with Stage III N2 NSCLC, including surgery [with neoadjuvant or ad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aac4f3a3efd14f977026029032d27cee
https://europepmc.org/articles/PMC8107728/